Endothelin-1 Dosing & Reconstitution Guide

Endothelin-1 is primarily administered via intravenous infusion in research contexts. This method allows for precise control over dosing and rapid adjustments as needed during experimental procedures. The frequency of administration may vary, typically involving either a single dose or short-duration infusions, depending on the specific objectives of the study. Research protocols have reported a dose range of 0.5 to 5 ng/kg/min for human subjects, with variations based on the design and goals of individual studies. It is crucial to consider the pharmacokinetics of ET-1, which can influence the overall effectiveness and outcomes of the research. Researchers should remain vigilant about the potential for variability in responses due to factors such as individual physiological differences and the specific context of the study.

Endothelin-1 is not employed as an exogenous therapeutic agent; rather, its endogenous overproduction is associated with various pathophysiological conditions, including pulmonary hypertension, heart failure, chronic kidney disease, and systemic hypertension. Experimental infusions of ET-1 have been shown to induce significant vasoconstriction, hypertension, and decreased cardiac output, highlighting the compound's potent effects on the cardiovascular system. As such, while specific contraindications do not apply to ET-1 when used in research settings, it is important to note that endothelin receptor antagonists, such as bosentan, carry warnings for use during pregnancy (classified as teratogenic, category X), significant hepatic impairment, and concurrent administration with cyclosporine. These safety considerations underscore the necessity of conducting thorough risk assessments when designing studies involving ET-1.